<DOC>
	<DOCNO>NCT01658033</DOCNO>
	<brief_summary>The objective phase II study evaluate efficacy safety avastin plus modified FOLFOX6 regimen HER-2 negative metastatic breast cancer patient . Fifty-five patient enrol study .</brief_summary>
	<brief_title>Bevacizumab Plus Modified FOLFOX6 Regimen Salvage Treatment Metastatic Breast Cancer ( MBC ) Patients</brief_title>
	<detailed_description>Anthracyclines taxanes frequently use agent breast cancer , adjuvant first-line metastatic settings.For patient respond relapse early administration taxane anthracycline regimen , clearly need explore new combination schedule drugs.Oxaliplatin show promising activity MBC either monotherapy combination 5-fluorouracil ( 5-FU ) without leucovorin ( LV ) . Avastin target therapy proven efficacy treatment MBC . Avastin plus FOLFOX regimen show synergetic effet use standard trial metastatic colorectal cancer patient . Based reason , initiate phase II study evaluate efficacy safety avastin plus modified FOLFOX6 regimen HER-2 negative metastatic breast cancer patient .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<criteria>1. age &gt; =18years 2 . Eastern Cooperative Oncology Group ( ECOG ) performance status ( PS ) &lt; =2 life expectancy &gt; = 12 week ; 3. histologicalproven , HER2 negative measurable stage IV disease ; 4. exposure anthracyclines , taxanes either neoadjuvant/adjuvant metastatic setting document disease progression firstline secondline treatment 5 . Patients previously treat radiotherapy eligible study , provide measurable disease exist outside radiation field . 6 . At least 3 week prior chemotherapy radiotherapy . At least 2 week prior endocrine therapy . 1 . Patients active infection serious underlie medical condition 2 . Patients prior treatment 5FU infusion and/or oxaliplatin therapy 3 . Inadequate bone marrow , liver , renal , medullary , cardiac function 4 . Evidence spinal cord compression brain metastasis 5 . History another malignancy within last five year except cure basal cell carcinoma skin carcinoma insitu uterine cervix contralateral breast cancer 6 . Pregnant lactate woman 7 . Serious uncontrolled intercurrent infection 8 . History evidence inherit bleed diathesis coagulopathy risk bleed 9 . Serious nonbleeding wound , peptic ulcer bone fracture 10 . Prior dihypopyrimidine dehydrogenase deficiency 11 . Hypersensitivity Chinese hamster ovary cell product recombinant human humanlised antibody</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>Metastatic Breast Cancer , Her-2 negative Breast Cancer</keyword>
	<keyword>Avastin , FOLFOX regimen</keyword>
</DOC>